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Manuel A. Vázqueza,b,1, Inés P. Mariñoc,d,*,1, Oleg Blyusse,d, Andy Ryand, Aleksandra Gentry-Maharajd,
Jatinderpal Kalsid, Ranjit Manchandad,f, Ian Jacobsd,g,h, Usha Menond,2, Alexey Zaikind,i,j,2
a Department of Signal Theory and Communications, Universidad Carlos III de Madrid, Leganés 28911,
Madrid, Spain.
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Abstract
We present a quantitative study of the performance of two automatic methods for the early detection of
ovarian cancer that can exploit longitudinal measurements of multiple biomarkers. The study is carried out
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for a subset of the data collected in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
We use statistical analysis techniques, such as the area under the Receiver Operating Characteristic (ROC)
curve, for evaluating the performance of two techniques that aim at the classification of subjects as either
healthy or suffering from the disease using time-series of multiple biomarkers as inputs. The first method
relies on a Bayesian hierarchical model that establishes connections within a set of clinically-interpretable
parameters. The second technique is a purely discriminative method that employs a recurrent neural
network (RNN) for the binary classification of the inputs. For the available dataset, the performance
of the two detection schemes is similar (the area under ROC curve is 0.98 for the combination of three
biomarkers) and the Bayesian approach has the advantage that its outputs (parameters estimates and
their uncertainty) can be further analysed by a clinical expert.
Keywords: Ovarian cancer; biomarkers; deep learning; recurrent neural networks; Markov chain; Monte
Carlo; Gibbs sampling; Change-point detection; Bayesian estimation.
1 Introduction 1
Ovarian cancer remains the fifth most common cause of cancer-related deaths among women, with more 2
than 150,000 annual deceases worldwide. Most cases occur in post-menopausal women (75%), with an 3
incidence of 40 per 100,000 per year in women aged over 50. The early detection of this disease increases 4
5-year survival significantly, from 3% in Stage IV to 90% in Stage I [1]. Therefore, it is important to 5
design efficient methods for early detection. 6
The screening and initial procedures for the detection of ovarian cancer are often carried out by testing 7
serum biomarkers that are known to correlate with the appearance of tumours. In particular, the serum 8
biomarker Canger Antigen 125 (CA125) is the most commonly used oncomarker in the screening of ovarian 9
cancer [2–5]. However, other serum biomarkers have been reported to be associated with the development 10
of ovarian cancer [6–8] and it has been recently suggested that they can be used in combination with 11
CA125 [8–14]. The biomarker that has received more attention is the Human Epididymis Protein 4 (HE4), 12
which has been used in the ROMA (Risk of Ovarian Malignancy Algorithm) to discriminate ovarian cancer 13
from benign diseases [9, 15] as well as in different panels for the purpose of early detection [7, 10, 11]. In a 14
study within the Prostate Lung Colorectal and Ovarian (PLCO) cancer screening trial [16], HE4 was the 15
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second best marker after CA125, with a sensitivity of 73% (95% confidence interval 0.60 – 0.86) compared 16
to 86% (95% confidence interval 0.76 – 0.97) for CA125 [17,18]. Another serum biomarker, glycodelin, 17
has also shown promising performance in the detection of ovarian cancer [12,19,20]. 18
Recently, time series data from multiple biomarkers, including CA125, HE4 and glycodelin, have been 19
jointly analysed to determine whether the level of these markers changed significantly and coherently at 20
specific time instants [6], associating this fact with the development of tumours. The focus in [6] was placed 21
on the detection of change-points for different biomarkers, by estimating the probability of coincidences 22
as well as the probability of the change-point of a given biomarker appearing (and being detected) 23
earlier than others. As a consequence, it was suggested that the combined detection of change-points in 24
several biomarkers could be exploited for early diagnosis of ovarian cancer. In this paper we address the 25
quantitative study of this automatic diagnostic technique using statistical analysis tools. 26
In particular, we study the trade-off between sensitivity (proportion of correctly detected positives) 27
and specificity (proportion of correctly detected negatives) of a detection procedure that relies on the 28
Bayesian change-point (BCP) model described in [6] which, in turn, is a version of the model proposed 29
originally in [21] for the ROCA (Risk of Ovarian Cancer Algorithm) scheme. The quantitative analysis is 30
carried out for a subset of the data collected in the UK Collaborative Trial of Ovarian Cancer Screening 31
(UKCTOCS) [22]. It involves time-series of CA125, HE4 and glycodelin for both healthy subjects (controls) 32
and diagnosed patients (cases). 33
The decisions made by the BCP model involve estimating a number of parameters that admit a natural 34
clinical interpretation. Although parsimony is always a desirable property to have in any model, accuracy 35
(measured in terms of sensitivity and specificity) is here the ultimate goal. Hence, we also consider machine 36
learning-based schemes which are often capable of modeling more complex mappings (between a set of 37
measurements and the corresponding output) at the expense of some interpretability. 38
Deep learning (DL), and Recurrent Neural Networks (RNNs) in particular, have become important 39
tools in classification tasks that involve the processing of ordered sequences of data [23]. Such methods 40
have achieved state-of-the-art performance in applications such as handwriting [24], speech recognition [25] 41
or image caption generation [26]. RNNS have also found many applications in the clinical field for tasks 42
involving the classification of time series. In [27] a Long Short-Term Memory (LSTM) RNN is trained to 43
classify diagnoses from pediatric intensive care unit (PICU) data. The same kind of data is fed to an 44
RNN in [28] in order to predict mortality rates for patients in the intensive care unit. A Gate Recurrent 45
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Unit (GRU) is proposed in [29] for heart failure prediction. The authors of [30] use RNNs to assess the 46
stress level of drivers from physiological signals coming from wearable sensors. In this work, we deploy a 47
simple RNN for discriminating between women with ovarian cancer and healthy controls based on an 48
ovarian cancer screening test that combines multiple biomarkers. The main challenge in applying DL in 49
this context is the relatively small size of the dataset, which imposes some constraints on the kind of 50
neural architectures that can be successfully trained without overfitting. 51
The ultimate goal in this paper is to carry out a comparison between these two different strategies 52
(BCP and RNN) highlighting the advantages and disadvantages of both techniques. The study of both 53
approaches, however, clearly shows that combining longitudinal time series of different biomarkers can 54
improve the classification of pre-diagnosis samples regardless of the method. 55
The rest of this paper is organised as follows. Section 2 is devoted to the description of the dataset. 56
Section 3 is devoted to a brief description of the Bayesian change-point method and the classification and 57
statistical analysis carried out with it. In Section 4 the recurrent neural network technique is presented as 58
well as the training procedure. The results obtained for both methods are presented and discussed in 59
Section 5 and, finally, Section 6 is devoted to dicussion and conclusions. 60
2 Data 61
The two methods have been applied to a dataset from the multimodal arm [6] of the UK Collaborative Trial 62
of Ovarian Cancer Screening (UKCTOCS, number ISRCTN22488978; NCT00058032) [22], where women 63
underwent annual screening tests using the blood tumour marker CA125. Biomarkers HE4 and glycodelin 64
assays were additionally performed on stored serial samples from a subset of women in the multimodal 65
arm diagnosed with ovarian cancer and controls. The dataset included 179 controls (healthy women) and 66
44 cases (diagnosed women): 35 cases of invasive epithelial ovarian cancer (iEOC), 3 cases of fallopian 67
tube cancer and 6 cases of peritoneal cancer. Out of these 44 cases, 16 are early stage (International 68
Federation of Ginecology and Obstetrics, FIGO [31], stages I and II) and 28 are late stage (FIGO stages 69
III and IV). In terms of histology, there are 27 serous cancers, 2 papillary, 3 endometrioid, 2 clear cell, 3 70
carcinosarcoma, and 7 not specified cancers. Each control has 4 to 5 serial samples available (177 controls 71
with 5 samples and 2 controls with 4 samples) and each case has 2 to 5 serial samples available (24 cases 72
with 5 samples, 10 cases with 3 samples and 10 cases with 2 samples). For healthy women, the range 73
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of age is 50.3–78.8 years and the average age over all women and samples is 63.6 years. On the other 74
hand, the range of ages for cases is 52.0–77.4 years and the average age over all women and samples is 75
65.5 years. A detailed classification of the women with cancer is shown in Table 1, indicating the range of 76
ages and the average age of the different subgroups. 77
Table 1. Classification of cases, showing the range of ages and the average age over the corresponding
women and samples.
Histology Stages number of women range of ages average age
serous cancers
I-II 9 [52.0-69.0] 61.3
III-IV 18 [54.9-76.7] 66.6
papillary
I-II 1 [68.1-69.2] 68.6
III-IV 1 [55.2-57.2] 56.2
endometrioid
I-II 2 [60.3-64.3] 62.7
III-IV 1 [67.6-68.7] 68.1
clear cell
I-II 2 [57.0-77.4] 67.2
III-IV 0 0 0
carcinosarcoma
I-II 0 0 0
III-IV 3 [60.0-67.2] 63.7
not specified
cancers
I-II 2 [72.7-74.2] 73.5
III-IV 5 [62.5-73.0] 67.8
All serum samples were assayed for CA125, glycodelin and HE4 using a proprietary multiplexed 78
immunoassay based on Luminex technology which was developed and run by Becton Dickinson. 79
It should be noted here that all the biomarker measurements have been modified via a logarithmic 80
transformation, as detailed in [12, 21], in the form of Y = log(Z + 4), where Z is the value of a particular 81
marker. 82
Traditionally, single-biomarker time-series have been employed for the screening of ovarian cancer 83
patients, particularly CA125 data. Recently, a few studies [6, 12, 32, 33] have suggested that different 84
biomarkers can be combined into multidimensional time-series and can lead to more accurate diagnosis. 85
We explore this approach in the sequel. 86
3 Bayesian Change-Point Method 87
3.1 Bayesian model 88
In order to analyse the available data, we adopt the Bayesian change-point model (BCP) described in [6,21] 89
and outlined in Fig. 1. Let yij denote the log-transformed measurement of the biomarker Z (where Z 90
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can be any of CA125, HE4 or glycodelin) for the i-th woman in the study at age tij . The number of 91
measurements for the i-th subject is denoted ki, so the time series consists of measurements collected at 92
ages ti1, . . . , tiki . The time tij of a measurement yij can depend on previous values yij′ , j
′ < j. 93
There are parameters in the model that are common to all women, namely those in the set C = 94
{µθ, µγ , σ2θ , σ2γ , σ2, π}, and parameters specific to each subject, namely Si = {θi, Ii, τi, log γi}. A key 95
parameter in the study to be carried out is the unobserved binary indicator Ii, which serves to determine 96
whether the corresponding biomarker of the i-th woman suffers or not a significative change in its behaviour. 97
The indicator Ii for each woman is assumed to follow, a priori, a Bernoulli distribution with success 98
probability π, where π represents the proportion of women for which we a priori expect a significant 99
change in the time-evolution of the biomarker level, i.e., a change-point in the time series. We have chosen 100
















Fig 1. Scheme of the hierarchical Bayesian model. Source: Fig. 1 from Ref. [6].
When the indicator of a given woman is Ii = 0 (expected for healthy women), all log-transformed 102
measurements of this woman, yij (j = 1, . . . , ki), are assumed to be modelled by a normal distribution 103
with mean denoted E(yij |tij , Ii = 0) = θi and variance σ2. This mean, θi, specific for each woman, is 104
also assumed to follow a normal distribution with mean and variance denoted, respectively, as µθ and 105
σ2θ , common to all women. We have chosen the same prior distributions as in [6] for σ
2, µθ and σ
2
θ . In 106
particular, σ2 ∼ IG(2.05, 0.1), µθ ∼ N (2.75, 1) and σ2θ ∼ IG(2.04, 0.065), where N (a, b) denotes a normal 107
distribution with mean a and variance b and IG(a, b) denotes the inverse gamma distribution with mean 108
b/(a− 1) and variance b2/[(a− 1)2(a− 2)]. 109
On the other hand, when the indicator of a given woman is Ii = 1 (expected for women with 110
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ovarian cancer), the corresponding measurements of this subject are assumed to be modelled by a normal 111
distribution with mean represented by the piecewise linear function E(yij |tij , Ii = 1) = θi + γi(tij − τi)+ 112
and variance σ2 (the same as before). The notation (·)+ denotes the positive part of the expression 113
between parentheses, γi represents the positive increase of the function that occurs after some time instant 114
τi, referred as the change-point of the time series, and θi is modelled as explained above. As in [6], log γi is 115
assumed to follow a normal distribution with mean and variance denoted, respectively, as µγ , σ
2
γ , common 116
to all women. The same prior distributions as in [6] have also been chosen for µγ and σ
2
γ and τi, namely 117
µγ ∼ N (1.1, 0.1), σ2γ ∼ IG(2.2, 0.12) and τi ∼ T N (di − 2, 0.752, [di − 5, di]), where di denotes the age of 118
patient i at the time of the last measurement and T N (a, b, c) represents truncated normal distributions, 119
with mean a, variance b and restricted to the interval c. 120
The posterior probability distributions for all unknown parameters of the model can be approximated 121
using the Metropolis-within-Gibbs (MwG) sampling algorithm described in detail in [6]. This algorithm 122
iteratively generates samples from the distribution of each parameter conditional on the current values of 123
the other parameters. It can be shown that the resulting sequence of samples yields a Markov chain, and 124
the stationary distribution of that Markov chain is the joint posterior probability distribution [34]. This is 125
done with every biomarker, that is, CA125, HE4 and glycodelin. 126
3.2 Detection Method 127
Unlike in [6], where the focus was placed on the change-point instant τi and its coherence across different 128
biomarkers (i.e., whether the slope of different biomarkers series changed simultaneously or not), in this 129
paper we propose to asses whether the i-th subject has ovarian cancer or not based on the expected value 130
of the indicator variable Ii given the available data. 131
Let m be the number of subjects in the dataset. In order to compute the expectation of Ii, i = 1, . . . ,m, 132
we run the MwG algorithm described in [6] to produce a chain of 10, 000 entries. Each entry of the chain 133




C, which includes the common 134
parameters in C and all subject-specific parameters. The first 5, 000 entries are removed (to ensure that 135
the chain has converged) and the expected value of each Ii (i ∈ {1, . . . ,m}) is estimated using the 5, 000 136




i =: Îi, where I
(k)
i is the k-th sample of 137
the i-th indicator in the Markov chain. 138
Detection can be carried out by comparing Îi to a threshold 0 < α < 1, in such a way that 139
PLOS 7/20
• if Îi < α the i-th subject is considered healthy, and a negative output is produced, and 140
• if Îi > α the disease is detected and a positive output is produced. 141
Some remarks are in order: 142
• The detection threshold α can (and should) be optimised using the available data. In Section 5 we 143
compute and plot the ROC curve that results from trying different values of α in the interval [0, 1] 144
for the dataset described in Section 2. This curve can be used to select the value of α that yields 145
suitable specificity (true negative rate) and sensitivity (true positive rate) values. 146
• The BCP model and the estimator Îi can be used for “soft” detection. Intuitively, a value of Îi well 147
above the selected α suggests a very confident positive (correspondingly, Îi << α points towards a 148
clear negative), while a value of Îi close to α may trigger different tests or the inspection of that 149
subject’s data by an expert clinician. 150
• The procedure can be naturally used on multiple biomarkers (and, indeed, we present such results 151
in Section 5). When we compute the estimator Îi for several biomarkers we adopt the convention 152
that the outcome is positive if Îi > α for at least one biomarker, while it is negative if Îi < α for all 153
biomarkers. ROC curves (obtained by varying the threshold α) are displayed in Section 5 for the 154
single-biomarker and multiple-biomarker cases. 155
4 Recurrent Neural Network 156
4.1 Network architecture 157
In a machine learning approach, we must decide whether a subject is healthy or not based on the value of 158
(at most) three features, given by the measurements of the biomarkers (CA125, HE4, and glycodelin), 159
and their corresponding time stamp. This is a small number of features and, when considering a deep 160
learning approach, we should be careful to choose a network architecture that is simple enough as to avoid 161
overfitting. With that in mind, we consider the most basic RNN followed by a dense layer, as shown in 162
Fig. 2. For the i-th subject, the input to the network is given by the sequence xi1,xi2, · · · ,xiki where 163
xij = [tij , yij ]
>
is a 2 × 1 column vector whose first element is the age of the subject, tij , and whose 164





















Fig 2. Network architecture for a single biomarker.
be any of CA125, HE4 or glycodelin) for the i-th subject in the study at age tij . The hidden state of the 166
network right before processing the j-th input from the i-th subject, xij , is given by the H × 1 (column) 167
vector sj−1, where H is the number of the hidden neurons. Then, the operation of the RNN is described 168
by the equation 169
sj = f (Wihxij + bih + Whhsj−1) (1)
where Wih is the H×2 input-hidden projection matrix, Whh is the hidden layer (recurrent) kernel matrix 170
of size H ×H, bih is a H × 1 bias vector, and f(·) is an (element-wise) activation function. The latter is 171
here the hyperbolic tangent, though other (usually non-linear) functions such as a Rectified Linear Unit 172
(ReLU) or sigmoid function are also possible [23]. When the last sample for the i-th subject, xiki , is fed 173






where σ(x) = 1/ (1 + e−x) is the sigmoid function, who is the H × 1 hidden-output weights vector, s̃ki is 175
the state vector ski after dropout [23], and bho is the (scalar) output bias. 176
Matrices Whh and Wih, along with vectors bih and who, and the scalar bho constitute the parameters 177







− (oi log(ôiki) + (1− oi) log(1− ôiki)) , (3)
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where N is the number of samples (subjects) seen during training and oi is the true label (1 for cases, 180
0 for controls) for the i-th subject. Notice that the RNN provides an output for every input but only 181
the last one, ôiki , is considered in the cost function. Minimization of the loss function is carried out by 182
means of stochastic gradient descent (SGD) with dynamic learning rates updated according to the Adam 183
algorithm [23]. 184
When more than one biomarker is available, we use the above architecture as building block and 185






Fig 3. Network architecture for biomarkers CA125 and HE4.
186
series of every biomarker is summarised by the last state of an RNN, and the two resulting H × 1 vectors 187
are concatenated to give an overall state that, after dropout, is processed by a fully connected layer. 188
Extension to three (or more) markers is straightforward. 189
4.2 Training, classification and statistical analysis 190
Rather than splitting the data into a training and test sets, and due to the small number of data, we 191
evaluate the performance of the RNN using cross validation. This entails partitioning the dataset into 192
K = 5 equal sized disjoint sets or folds, and in turn evaluate the performance on each one while training on 193
the rest. Ultimately, this yields a prediction for every subject in the dataset, which allows for computing 194
the usual performance metrics. 195
The above RNN architecture has two hyperparameters: the number of neurons in the hidden state, 196
H, and the amount of dropout used for regularisation. Additionally, the training phase gives rise to yet 197
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another hyperparameter, which is the number of epochs. These three hyperparameters are selected by 198
another (inner) level of cross-validation. Indeed, 10-fold cross-validation is used on every training set to 199
compare the performance of the model for every possible combination of the values of the hyperparameters. 200
The actual training is then performed using the best combination of hyperparameters (over the entire 201
training set). 202
During training, the biomarker’s measurements are normalised so that, across all the samples of all 203
the subjects, the mean is 0 and the variance is 1. This is common practice in most machine learning 204
algorithms, and it is meant to speed up optimisation. Notice that the empirical means and variances (one 205
per feature) used for normalisation during training must be kept and applied on any subsequent sample 206
that is to be classified (and, in particular, over the test set). 207
Regarding the initialization of the weights, different strategies are used for different layers of the 208
network. In particular, Whh is set to a random orthogonal matrix as proposed in [36], Wih and who are 209
initialized using Glorot’s scheme [37], and bias vector bih and scalar bho are set to zero. 210
5 Results 211
In this section we assess the performance of two schemes that we have described in Section 3 (BCP) and 212
Section 4 (RNN), in terms of their sensitivity and specificity. These two metrics, for different values of 213
the corresponding threshold, are illustrated by the Receiver Operating Characteristic (ROC) curve. 214
Figure 4 shows the AUC along with the corresponding confidence interval for every individual biomarker, 215
as well as every combination of biomarkers encompassing CA125. In both algorithms it is clear that, when 216
considering a single biomarker, CA125 is the one yielding the best performance (a larger AUC in a narrower 217
confidence interval). When using several biomarkers, the best results are obtained when combining CA125 218
with HE4. Specifically, in both algorithms the AUCs for “CA125+HE4” and “CA125+HE4+Gly” are 219
≈ 0.98. Figures 5 and 6 show, respectively, the ROC curves for the BCP and RNN schemes. In both 220
cases, the plot on the left focuses on the results for a single biomarker, while the plot on the right depicts 221
the curves for combinations of biomarkers (along with the curve of CA125 that serves as a reference). 222
The confidence intervals given in Figure 4 suggest that the differences between the AUC within and 223
across algorithms are not statistically significant. Specifically, when comparing both schemes (the one 224
based on RNNs and the one based on BCP) for a standalone biomarker or combination of biomarkers, 225
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AUC Confidence Interval [l,u] l u
RNN
CA125 0.963
0.85 0.9 0.95 1
0.921 1
HE4 0.912 0.86 0.965
Gly 0.904 0.842 0.965
CA125+HE4 0.977 0.951 1
CA125+Gly 0.966 0.924 1
CA125+HE4+Gly 0.976 0.944 1
BCP
CA125 0.956 0.908 1
HE4 0.93 0.879 0.981
Gly 0.929 0.872 0.986
CA125+HE4 0.985 0.969 1
CA125+Gly 0.976 0.947 1
CA125+HE4+Gly 0.98 0.962 0.998
Fig 4. Area Under the Curve with 95% confidence intervals.






































Fig 5. ROC curves and area under ROC curve obtained by the Bayesian Change-point
method for different biomarkers: (a) when considering a single biomarker (CA125, HE4 or
glycodelin), (b) when considering different combinations of then three biomarkers.
the estimated AUCs are very close and the corresponding confidence intervals overlap to a great extent. 226
Hence, it is hard to say one algorithm performs better than the other. On the other hand, when focusing 227
on a certain algorithm, although using the three biomarkers increases the AUC and narrows down the 95% 228
confidence interval, there is still some overlap when the latter is compared with the confidence intervals 229
for individual biomarkers. 230
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Fig 6. ROC curves and area under ROC curve obtained by the Recurrent Neural Network
for different biomarkers: (a) when considering a single biomarker (CA125, HE4 or glycodelin), (b)
when considering different combinations of the three biomarkers.
In order to assess whether, for a given algorithm, the differences between AUCs for different com- 231
binations of biomarkers are statistically significant, we have computed the p-value of hypothesis tests 232
comparing, pairwise, every possible combination of biomarkers. Notice that here we are slightly abusing 233
notation, and we are also referring to a single biomarker, e.g., “CA125”, as a combination. The results are 234
shown in Figure 7. Those tests in which the null hypothesis (“the compared AUCs are equal”) is rejected 235
at a 0.05 significance level are highlighted in bold font. Some remarks are in order 236
• In both algorithms, the AUC attained using the three biomarkers is different (better) from that 237
achieved using only HE4 or only Gly; additionally, in the RNN-based algorithm, it is also the case 238
that using all the biomarkers yields an improved AUC as compared to using only CA125. 239
• In both algorithms the AUC using only Gly is different from that using any of the two-marker 240
combinations; in the RNN algorithm the hypothesis that the AUC using only Gly is the same as 241
that using only CA125 is also rejected. 242
• In both algorithms, we must also reject the hypothesis that the results for HE4 only are equal to 243
those obtained using “CA125+HE4” combination. 244
For the problem at hand, one of the most important performance metrics is the sensitivity. In order to 245
compare effectiveness of BCP- and RNN-based schemes for this metric, we set the corresponding decision 246
threshold of each algorithm at a value such that a minimum specificity of 90% is attained, and evaluate the 247
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Hypothesis test RNN BCP
CA125 vs HE4 0.127 0.461
CA125 vs Gly 0.044 0.435
CA125 vs CA125+HE4 0.121 0.226
CA125 vs CA125+Gly 0.372 0.402
CA125 vs CA125+HE4+Gly 0.04 0.317
HE4 vs Gly 0.803 0.97
HE4 vs CA125+HE4 0.024 0.027
HE4 vs CA125+Gly 0.105 0.092
HE4 vs CA125+HE4+Gly 0.035 0.045
Gly vs CA125+HE4 0.011 0.03
Gly vs CA125+Gly 0.029 0.037
Gly vs CA125+HE4+Gly 0.007 0.04
CA125+HE4 vs CA125+Gly 0.319 0.335
CA125+HE4 vs CA125+HE4+Gly 0.921 0.171
CA125+Gly vs CA125+HE4+Gly 0.103 0.618
Fig 7. p-values obtained for the hypothesis tests assessing whether the AUCs attained by different
combinations of biomarkers are different (in both the RNN- and BCP-based methods).
sensitivity afterwards. The results are shown in Figure 8. When a single biomarker is used, the sensitivity 248
of the BCP algorithm is slightly higher than that exhibited by the RNN in each of the three cases (CA125, 249
HE4, and Gly), although the corresponding confidence intervals overlap pairwise, and hence the differences 250
are not statistically significant. When using combination of biomarkers, both algorithms show a noticeable 251
increase in the sensitivity. Specifically, when considering the three biomarkers, both the RNN and the 252
BCP algorithm exhibit a sensitivity of around 0.98, whereas when only CA125 is exploited, the sensitivity 253
attained by the RNN algorithm is ≈ 0.91 and that achieved by the BCP-based scheme is ≈ 0.93. In both 254
algorithms, there is overlap between the confidence intervals for CA125 and CA125+HE4+Gly, but it 255
is clear that using the combination the confidence interval is significantly narrower. Hence, it could be 256
argued that both algorithms benefit from using all the three biomarkers. 257
6 Discussion and Conclusions 258
We have explored two different approaches to tackle the problem of ovarian cancer detection from a 259
sequence of longitudinal measurements of several biomarkers. The first approach relies on a Bayesian 260
hierarchical model whose fundamental assumption is that measurements taken from case subjects exhibit 261
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sensitivity Confidence Interval [l,u] l u
RNN
CA125 0.909
0.6 0.7 0.8 0.9 1
0.818 0.977
HE4 0.773 0.636 0.886
Gly 0.818 0.705 0.932
CA125+HE4 0.955 0.886 1
CA125+Gly 0.909 0.818 1
CA125+HE4+Gly 0.977 0.886 1
BCP
CA125 0.932 0.841 1
HE4 0.818 0.705 0.932
Gly 0.886 0.773 0.964
CA125+HE4 0.977 0.932 1
CA125+Gly 0.977 0.909 1
CA125+HE4+Gly 0.977 0.932 1
Fig 8. Sensitivity for a 90% specificity.
a changepoint in one or several biomarkers. The second approach is a purely discriminative machine 262
learning algorithm based on the use of RNNs, a kind of artificial neural network specially suited for the 263
processing of ordered sequences of data. 264
Our experimental results (relying on real data) show that, regardless of the method, CA125 is the 265
single biomarker yielding the best performance, as measured by either the AUC or the sensitivity attained 266
for a fixed specificity. When using several biomarkers, both algorithms get a performance boost, although 267
the latter is not always statistically significant. For instance, 95% confidence level hypothesis tests suggest 268
that the joint use of CA125, HE4 and glycodelin biomarkers increases the performance of both methods 269
as compared to using either HE4 or glycodelin alone. However, only for the RNN-based scheme, the 270
combination of the three biomarkers seems to improve the AUC obtained by CA125 alone. In any case, 271
both methods exhibit nearly the same performance. Similar conclusions can be drawn when looking at 272
the sensitivity of the algorithms for a fixed specificity at 90%. In such a case, the confidence interval 273
for the sensitivity obtained using CA125 alone, on one hand, and the three biomarkers, on the other 274
hand, overlap. Hence we cannot rule out the hypothesis that both sensitivities are equal. However, 275
when using CA125, HE4 and glycodelin, the estimated sensitivity is noticeably higher and, moreover, the 276
corresponding confidence interval is markedly narrower. 277
PLOS 15/20
Since the performances of the two approaches are ultimately comparable when every available biomarker 278
is used, other considerations must be taken into account when choosing one over the other. If interpretability 279
is a concern, the parameters estimated by the BCP algorithm have a physical intuitive interpretation, 280
whereas the weights in a neural network (NN) are usually much harder to interpret. On the other hand, 281
RNNs are able to integrate different markers more naturally. In connection with this, RNNs might also 282
be able to perform some kind of feature selection by way of weighting more heavily a certain biomarker 283
(accounting for previously seen values) whereas in the BCP scheme, every biomarker is considered equally 284
important. 285
RNNs, and NNs in general, usually need a large amount of training data in order to obtain a model 286
that achieves good generalization capabilities. In order to avoid overfitting, regularization techniques, 287
such as dropout, can be used when the dataset is small, but it is not always straightforward how or where 288
to apply them. On the contrary, generative models like BCP make the most of the available data while 289
accounting for the uncertainty given by the prior. 290
Regarding the RNN approach, future works should use a larger dataset which will allow to exploit the 291
full potential of deep learning in the problem at hand. Also, many other NN architectures are possible, 292
but exploring them would demand a paper of its own. 293
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